turimycin: macrolide antibiotic from Streptomyces hygroscopicus JA 6599; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
leucomycin V : A macrolide antibiotic produced by Streptomyces kitasatoensis, showing activity against a wide spectrum of pathogens. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5282189 |
| CHEBI ID | 31753 |
| SCHEMBL ID | 5035766 |
| MeSH ID | M0057206 |
| Synonym |
|---|
| a 6599 |
| 39405-35-1 |
| 22875-15-6 |
| leucomycin v |
| syneptine |
| stereomycine |
| 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,1 |
| turimycin |
| antibiotic ja-6599 |
| antibiotic a 6599 |
| 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde |
| CHEBI:31753 |
| [(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-{[(2s,3r,4r,5s,6r)-5-{[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca |
| AKOS015896458 |
| SCHEMBL5035766 |
| Q6417876 |
| deisovaleryl leucomycin a1 |
| deacylleucomycin a1 |
| 4''-deacylturimycin h |
| vw9sy2s5wl , |
| glucopyranoside, 7-(formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-, beta-d- |
| unii-vw9sy2s5wl |
| glucopyranoside, 7-(formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-.alpha.-l-ribo-hexopyranosyl)-3-(dimethylamino)-, .beta.-d- |
| oxacyclohexadeca-11,13-diene-7-acetaldehyde, 6-((3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-.alpha.-l-ribo-hexopyranosyl)-3-(dimethylamino)-.beta.-d-glucopyranosyl)oxy)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-, (4r-(4r*,5s*,6s*,7r*,9r*,10r*,11e,13e,16r* |
| DTXSID501043929 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic properties of turimycin are similar to those of corresponding macrolide antibiotics, including tylosin." | ( Pharmacokinetic characteristics of the new veterinary antibiotic turimycin. Härtl, A; Hoffmann, H, ) | 0.65 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The absorption rate from the intestine was about 30%." | ( Pharmacokinetic characteristics of the new veterinary antibiotic turimycin. Härtl, A; Hoffmann, H, ) | 0.37 |
| Role | Description |
|---|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| leucomycin | |
| macrolide antibiotic | A macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 21 (95.45) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 26 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||